奎扎替尼

{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444260047
| ImageFile =Quizartinib.svg
| ImageSize =
| ImageAlt =
| PIN =N-(5-tert-Butyl-1,2-oxazol-3-yl)-N′-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea
| OtherNames =
| Section1 =
| Section2 =
| Section6 = {{Chembox Pharmacology
| Pharmacology_ref =
| ATCCode_prefix = L01
| ATCCode_suffix = EX11
| ATC_Supplemental =
| ATCvet =
| Licence_EU =
| INN =
| INN_EMA =
| Licence_US =
| Legal_status =
| Legal_AU =
| Legal_AU_comment =
| Legal_UK =
| Legal_UK_comment =
| Legal_US = Rx-only
| Legal_US_comment =

它是一种小分子受体酪氨酸激酶抑制剂。其分子靶点是FLT3，也称CD135（一种原癌基因）。

它在2019年10月在日本获许使用，2023年7月在美国得到批准。

参考文献
外部链接
*